FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2968843497> ?p ?o ?g. }

• W2968843497 endingPage "e199249" @default.
• W2968843497 startingPage "e199249" @default.
• W2968843497 abstract "<h3>Importance</h3> Sipuleucel-T was the first therapeutic cancer vaccine approved by the US Food and Drug Administration (FDA) in 2010. Although almost a decade has passed since its approval for the treatment of asymptomatic or minimally symptomatic castration-resistant prostate cancer (CRPC), there remains a paucity of literature describing safety data in the postmarketing period. <h3>Objective</h3> To describe the postmarketing safety experience for sipuleucel-T. <h3>Design, Setting, and Participants</h3> In this case series study, US reports for sipuleucel-T submitted to the FDA’s Adverse Event Reporting System were searched and reviewed between April 29, 2010, and December 31, 2017. This system is a spontaneous safety surveillance database for drug and therapeutic biologic products. The analysis of 3216 reports and select case reviews were undertaken between February and November 2018. <h3>Main Outcomes and Measures</h3> Descriptive statistics were used to assess adverse event reports for sipuleucel-T. Empirical Bayes Geometric Means (EBGM) and their 90% confidence intervals (CIs) were computed to identify disproportionate (ie, at least twice the expected) reporting of sipuleucel-T–event pairs. Selected adverse events and death reports were individually reviewed. <h3>Results</h3> In total, 3216 reports were identified for sipuleucel-T, of which 2014 (62.6%) were serious. For all included reports, the patients’ median (interquartile range) age was 73 (67-79) years, and 3149 were specified to be males. Chills (n = 318), malaise (n = 196), pyrexia (n = 189), culture positive (n = 184), fatigue (n = 180), and nausea (n = 173) were among the most commonly reported adverse events. Infusion-related reactions (EBGM, 12.1; 90% CI, 9.4-15.3), infections, vascular events, and transient ischemic attacks (EBGM, 2.9; 90% CI, 2.2-3.9) were reported disproportionately. Among 249 deaths for which relevant dates were available, 128 (51.4%) were reported within 30 days of a sipuleucel-T infusion, of which 81.2% included a specified cause of death; of these 104 deaths, there were 37 neoplasms (35.6%), 25 cardiac disorders (24.0%), 18 nervous system disorders (17.3%), and 9 infections (8.7%). <h3>Conclusions and Relevance</h3> Reported adverse events were generally consistent with the safety experience observed in prelicensure studies and described in the sipuleucel-T package insert. Off-label use among overtly symptomatic men with CRPC, reporting bias, or lack of product effectiveness may have influenced the reporting of deaths within 30 days of treatment initiation. With this overview of sipuleucel-T experience, the present study serves as a resource for health care professionals and patients as they weigh the risks and benefits of treatment in the context of all available therapeutic options for CRPC." @default.
• W2968843497 created "2019-08-22" @default.
• W2968843497 creator A5045745471 @default.
• W2968843497 creator A5047405171 @default.
• W2968843497 creator A5072745834 @default.
• W2968843497 date "2019-08-14" @default.
• W2968843497 modified "2023-10-16" @default.
• W2968843497 title "Adverse Events Associated With the Use of Sipuleucel-T Reported to the US Food and Drug Administration’s Adverse Event Reporting System, 2010-2017" @default.
• W2968843497 cites W1659741523 @default.
• W2968843497 cites W174327138 @default.
• W2968843497 cites W1913797671 @default.
• W2968843497 cites W1967342248 @default.
• W2968843497 cites W1975507802 @default.
• W2968843497 cites W1981809734 @default.
• W2968843497 cites W2048447659 @default.
• W2968843497 cites W2048507943 @default.
• W2968843497 cites W2088875727 @default.
• W2968843497 cites W2097930057 @default.
• W2968843497 cites W2103959341 @default.
• W2968843497 cites W2113791652 @default.
• W2968843497 cites W2122160078 @default.
• W2968843497 cites W2125293191 @default.
• W2968843497 cites W2132607654 @default.
• W2968843497 cites W2137545053 @default.
• W2968843497 cites W2146892067 @default.
• W2968843497 cites W2149752186 @default.
• W2968843497 cites W2151426785 @default.
• W2968843497 cites W2159423693 @default.
• W2968843497 cites W2168803832 @default.
• W2968843497 cites W2169258216 @default.
• W2968843497 cites W2282181907 @default.
• W2968843497 cites W2327497977 @default.
• W2968843497 cites W2593675800 @default.
• W2968843497 cites W2608364534 @default.
• W2968843497 cites W2768146862 @default.
• W2968843497 cites W2770265731 @default.
• W2968843497 cites W2898661793 @default.
• W2968843497 cites W2935880623 @default.
• W2968843497 cites W4233888847 @default.
• W2968843497 cites W4240826548 @default.
• W2968843497 doi "https://doi.org/10.1001/jamanetworkopen.2019.9249" @default.
• W2968843497 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6694390" @default.
• W2968843497 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31411714" @default.
• W2968843497 hasPublicationYear "2019" @default.
• W2968843497 type Work @default.
• W2968843497 sameAs 2968843497 @default.
• W2968843497 citedByCount "28" @default.
• W2968843497 countsByYear W29688434972019 @default.
• W2968843497 countsByYear W29688434972020 @default.
• W2968843497 countsByYear W29688434972021 @default.
• W2968843497 countsByYear W29688434972022 @default.
• W2968843497 countsByYear W29688434972023 @default.
• W2968843497 crossrefType "journal-article" @default.
• W2968843497 hasAuthorship W2968843497A5045745471 @default.
• W2968843497 hasAuthorship W2968843497A5047405171 @default.
• W2968843497 hasAuthorship W2968843497A5072745834 @default.
• W2968843497 hasBestOaLocation W29688434971 @default.
• W2968843497 hasConcept C121608353 @default.
• W2968843497 hasConcept C126322002 @default.
• W2968843497 hasConcept C197934379 @default.
• W2968843497 hasConcept C2777105317 @default.
• W2968843497 hasConcept C2777899217 @default.
• W2968843497 hasConcept C2778594517 @default.
• W2968843497 hasConcept C2778971682 @default.
• W2968843497 hasConcept C2780192828 @default.
• W2968843497 hasConcept C57658597 @default.
• W2968843497 hasConcept C71924100 @default.
• W2968843497 hasConceptScore W2968843497C121608353 @default.
• W2968843497 hasConceptScore W2968843497C126322002 @default.
• W2968843497 hasConceptScore W2968843497C197934379 @default.
• W2968843497 hasConceptScore W2968843497C2777105317 @default.
• W2968843497 hasConceptScore W2968843497C2777899217 @default.
• W2968843497 hasConceptScore W2968843497C2778594517 @default.
• W2968843497 hasConceptScore W2968843497C2778971682 @default.
• W2968843497 hasConceptScore W2968843497C2780192828 @default.
• W2968843497 hasConceptScore W2968843497C57658597 @default.
• W2968843497 hasConceptScore W2968843497C71924100 @default.
• W2968843497 hasIssue "8" @default.
• W2968843497 hasLocation W29688434971 @default.
• W2968843497 hasLocation W29688434972 @default.
• W2968843497 hasLocation W29688434973 @default.
• W2968843497 hasLocation W29688434974 @default.
• W2968843497 hasOpenAccess W2968843497 @default.
• W2968843497 hasPrimaryLocation W29688434971 @default.
• W2968843497 hasRelatedWork W1777403110 @default.
• W2968843497 hasRelatedWork W2592450025 @default.
• W2968843497 hasRelatedWork W2898266225 @default.
• W2968843497 hasRelatedWork W2968843497 @default.
• W2968843497 hasRelatedWork W2982021612 @default.
• W2968843497 hasRelatedWork W4220701557 @default.
• W2968843497 hasRelatedWork W4281861147 @default.
• W2968843497 hasRelatedWork W4283511242 @default.
• W2968843497 hasRelatedWork W4310255579 @default.
• W2968843497 hasRelatedWork W4323347657 @default.
• W2968843497 hasVolume "2" @default.
• W2968843497 isParatext "false" @default.
• W2968843497 isRetracted "false" @default.
• W2968843497 magId "2968843497" @default.

• next